Menactra Returns To Normal Schedule; FluMist Seeks CDC Contract
Executive Summary
FluMist CDC contract: MedImmune is negotiating a contract with the Centers for Disease Control & Prevention to supply its intranasal flu vaccine FluMist for the 2006-2007 season, VP & General Manager Mark Twyman says during a Oct. 25-26 meeting of CDC's Advisory Committee on Immunization Practices in Atlanta. The firm could supply the entire pediatric market by the 2008-2009 season, he says. Firm plans to produce 3 mil. doses of FluMist for the U.S. market for the current season and expects to have production, filling and distribution capacity for 20 mil. to 30 mil. doses for 2008-2009. MedImmune hopes to launch its refrigerator-stable version, CAIV-T (cold adapted influenza vaccine, trivalent), by next season. The firm hopes the non-freezer version will boost sluggish uptake...
You may also be interested in...
Sanofi Sees Blockbuster Sales For Menactra With New Indications, Capacity
Sanofi-Aventis expects new indications and additional manufacturing capacity to push its meningococcal conjugate vaccine Menactra over the €1 billion threshold in annual sales
Sanofi Sees Blockbuster Sales For Menactra With New Indications, Capacity
Sanofi-Aventis expects new indications and additional manufacturing capacity to push its meningococcal conjugate vaccine Menactra over the €1 billion threshold in annual sales
ACIP In Brief
Gardasil catches catch-up population: Merck's human papillomavirus vaccine Gardasil should be administered to females 13 to 26 years of age as part of a catch-up program and to girls ages 11 and 12 as a routine vaccination, the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices unanimously agreed June 29 in Atlanta. Published estimates of cost-effectiveness ratios for vaccination of 12-year-old females range from $14,600 to $24,300 per quality adjusted life-year. Panel members supported use of the quadrivalent vaccine in "special situations" for females that would normally not be vaccinated, including those with abnormal pap tests, genital warts, positive HPV tests, immunosuppression and who are lactating. The committee agreed that women found to be pregnant after receiving the initial dose of vaccination should delay completion of series until after pregnancy. Gardasil cleared FDA June 8 for prevention of cervical cancer and pre-cancers (1"The Pink Sheet" June 12, 2006, p. 3)...